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Background: Current studies on adherence to endocrine therapy in breast cancer patients suffer from
methodological limitations due to a lack of well-validated methods for assessing adherence. There is no gold
standard for measuring adherence. The aim of our study was to compare four different approaches for evaluating
adherence to anastrozole therapy for breast cancer with regard to concordance between methods.
Methods: Outpatients with early breast cancer treated with anastrozole completed the multi-method assessment
of adherence. We implemented a self-report scale (the Simplified Medication Adherence Questionnaire),
physician- ratings, refill records and determination of anastrozole serum concentration.
Results: Comparison of the four approaches using Spearman rank correlation revealed poor concordance across all
methods reflecting weak correlations of 0.2-0.4. Considering this data incomparability across methods, we still
observed high adherence rates of 78%-98% across measures.
Conclusion: Our findings contribute to the growing body of knowledge on the impact that methodological
aspects exert on the results of adherence measurement in breast cancer patients receiving endocrine treatment.
Our findings suggest that the development and validation of instruments specific to patients receiving endocrine
agents is imperative in order to arrive at a more accurate assessment and to subsequently obtain more precise
estimates of adherence rates in this patient population.
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Orally administered treatment with the new-generation
aromatase inhibitors (AIs) plays an important role in the
treatment of breast cancer resulting in substantial reduc-
tions in breast cancer recurrence [1,2]. In this regard it
might be reasonable to assume breast cancer patients to
be highly motivated and adherent to this treatment re-
gime due to the seriousness of their disease, having “too
much to lose” by not adhering [3]. Still, it has become
apparent that, despite the great efficacy of AI treatment,
non-adherence to adjuvant endocrine agents occurs fre-
quently [4,5].* Correspondence: Michael.hubalek@i-med.ac.at
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distribution, and reproduction in any mediumEvaluation of treatment adherence is, thus, a major
issue in breast cancer care [4]. The assessment of long-
term adherent behavior, however, is methodologically
challenging. Studies have yielded inconclusive results in-
dicating adherence rates between 20% and 100% across
different phases of antineoplastic treatment [6,7]. This
variability of non-adherence rates found in the literature
has been suggested to be attributed to heterogeneous
study designs as well as inconsistencies in methodo-
logical approaches. Among the latter the indirect meth-
ods of self-report, prescription refill and pharmacy
records have been predominately used in studies on ad-
herence to endocrine agents [3,4]. Direct methods which
are supposed to reveal more objective results due to the
assessment of medication consumption in an unmedi-
ated way have not been employed in respective studies.Med Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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urement available [8].
Current evidence indicates that the patterns of find-
ings on adherence might result more from the methods
used to study them than from the underlying conceptual
principles [9]. Highlighting the subsequent question as
one of the most important ones in the field of adherence
research, DiMatteo and Haskard [10] ask: “How are find-
ings [on adherence] influenced by the measurement
strategies?”
The type of measurement, whether direct or indirect
[11], is an important determinant of the respective
research finding [12]. DiMatteo and colleagues [13]
noted in their review on patient adherence and
treatment outcome that the adherence measurement
variables of self-report, continuous measures and multi-
method approaches moderated the adherence-outcome
effects, which again reflects the dependence of results
on the methodological approaches used. Moreover, both
direct and indirect methods are prone to error – impact-
ing on results. These methodological shortcomings seem
to limit the appropriate evaluation of adherence rates for
AI treatment, thereby hindering definitive conclusion
and accounting for great data variability [3,11].
Accordingly, Cantrell [14] claimed the understanding
of variations in adherence measurement to be an essen-
tial part of adherence research. Recognition and system-
atic assessment of the role of methodology seem to be of
utmost importance to be able to draw conclusions on
prevalence and correlates of (non-) adherence [10] as
well as to evaluate adherence-interventions [15]. Direct
comparison of the accuracy provided by various
measures is, however, only possible if the methods are
applied in the same patient population. In breast cancer
patients receiving endocrine therapy, to the best of our
knowledge, hardly any studies have compared various
adherence measures in relation to their concordance
[3,16].
Aims
In this study, we aimed at comparing four adherence
measurement methods, all of which were defined by the
WHO as state-of-the-art measurement of adherence [8],
for their concordance in breast cancer patients undergo-
ing anastrozole treatment. We compared self-report,
physician rating, determination of plasma concentration
and prescription refill.
In detail, we have addressed the following research
questions:
 Do different adherence measures reveal comparable
results?
 To what extent do early breast cancer patients
adhere to AI treatment?Methods
This study is part of a larger project referred to as
"Patient-reported outcomes in breast cancer patients
undergoing endocrine therapy: an observational study
of adherence (PRO-BETh)" at the Medical University
Innsbruck. The aim of PRO-BETh is to perform a multi-
method evaluation of adherence to endocrine treatment
in pre- and post-menopausal breast cancer patients.
Physical symptoms and psychosocial burden are assessed
using patient-reported outcome (PRO) measures and
analyzed in relation to their impact on adherence. In
addition, plasma concentrations of endocrine treatment
and pharmacogenetic aspects were investigated. For the
whole PRO-Beth study a total of 563 patients were
approached comprising pre- and postmenopausal
patients receiving any kind of endocrine treatment. 70
patients declined to participate resulting in an overall
participation rate of 87.6%. Data on physical symptoms
and psychosocial burden (PRO assessment) in the post-
menopausal patient group receiving any kind of aroma-
tase inhibitor treatment have been published elsewhere
[17]. Analyses on symptom burden in premenopausal
patients receiving tamoxifen as well as on pharmacoge-
netic aspects have not yet been completed. For the ana-
lysis presented herein, we only included patients
receiving anastrazole (not adjusted for menopausal state)
to provide group homogeneity.
Approval was obtained from the Ethics Committee of
Medical University Innsbruck.
Sample
Breast cancer outpatients treated at the Department of
Gynecology and Obstetrics (Innsbruck Medical Univer-
sity) between June 2009 and February 2011 were consid-
ered for enrolment. Patients were eligible for this
substudy of the PRO-BETh if they
– had a diagnosis of non-metastatic breast cancer,
– were undergoing adjuvant endocrine therapy with
anastrazole (>0.5 months after their primary
treatment)
– had no prior treatment with any endocrine agent or
any overt cognitive impairment
– were aged between 18 and 85 and
– were fluent in German and
– provided written informed consent.
Eligible patients were identified by searching the
department's medical records.
Procedure
Patients were approached at one of their routine three-
month follow-up appointments at the Department of
Gynecology and Obstetrics, Medical University
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completed the PRO-assessment of adherence (self-report
questionnaire) and Quality of Life (QOL). Further details
and results of the PRO-assessment are described else-
where [17]. Blood samples were collected after the com-
pletion of the questionnaires as part of routine blood
collection and subsequently sent to the Department of
Forensic Medicine (Medical University Innsbruck) for
analysis. Then, the routine medical check-up was
conducted after which the physicians completed their
adherence rating. All adherence data were collected
cross-sectionally with exception of those derived from
the refill records. The latter were collected retrospect-
ively for each patient (details are provided in the chapter
assessment instruments).
Clinical and sociodemographic variables were taken
from the clinical records. Refill records were obtained
from the insurance companies at the end of the assess-
ment period.
Adherence was defined as a function of the instrument
applied.
Assessment methods
A main focus of this study was the comparison of com-
monly used assessment methods for adherence. These
include self-report measures (SMAQ), proxy ratings by
the physician, refill records.
As a further measure for adherence we determined
AI-plasma concentrations. To the best of our knowledge,
this is the first study assessing AI-plasma concentrations
for the evaluation of AI adherence.
Self-report questionnaire (SMAQ)
For patient self-report, we decided to administer the
Simplified Medication Adherence Questionnaire (SMAQ)
originally validated in an HIV population [18], since
there is no questionnaire available that specifically
assesses treatment adherence to endocrine treatment for
early breast cancer. The SMAQ is a six-item, short self-
report questionnaire measuring the overall trend of
chronically ill patients' medication adherence and the ac-
curacy of medication intake (e.g. number of missed
doses). It is composed of the revised Morisky Scale (3
items in the original version) [19] and three additional
items which were supplemented by the developers of the
SMAQ. The following six questions compose the
SMAQ: 1. Do you ever forget to take you medicine? (re-
sponse format: yes-no), 2. Are you careless at times
about taking your medicine? (response format: yes-no),
3. Sometimes if you feel worse, do you stop taking your
medicines? (response format: yes-no), 4. Think back to
last week. How often did you not take your medicine? (5
point likert scale: “never” to more than “10 times”), 5.
Did you fail to take any of your medicine over the pastweekend? (response format: yes-no), 6. Over the past
three months, on how many days did you not take any
medicine at all? (resonse format: less than 2 times-more
than two times). According to the SMAQ a patient is
considered non-adherent in case of a positive response
(“yes”) to any of the questions 1–3 and 5 or/and more
than two doses missed over the past week (item 4) or/
and more than 2 days of non-medication intake during
the past 3 months (item 6) [18].
The SMAQ was translated into German following a
forward-backward translation process and adapted to the
requirements of this study by developing a scoring system
to replace the rigorous, dichotomous outcome (adherent-
non adherent). We developed a sum score across all ques-
tions by dichotomizing all items (score 1 = non adherent,
score 2 = adherent). The scores were then added to the
final score with a possible range between 6 and 12. The
dichotomization was done in the following: For item 6 the
answer “less than two times” was scored with 2 (adherent);
for item 4 the answer “never” was scored with 2 (adher-
ent) while the other categories were classified as non-
adherent (score 1). Item 1–3 and 5 stayed with the original
dichotomous response (no = score 2 = adherent; yes =
score 1 = non-adherent). Only patients with the highest
possible sum score (i.e. 12) were classified as adherent.
This corresponds to the 90% percentile which was chosen
following recommendations in the literature [20]. With a
moderate Cronbach’s Alpha of 0.67, the questionnaire
proved to be moderately reliable in this specific pa-
tient population. Patients completed the questionnaire
themselves.
Physician rating
For each patient, the clinical expert rating was per-
formed by the treating gynecologist/oncologist after the
patient’s three-month routine check-up via a dichotom-
ous classification yes (adherent) – no (non-adherent)
(same day of the other assessments). The experienced
physician classified patients as adherent or non-adherent
based on his or her clinical impression. Medical expert
ratings are an established method for assessing adher-
ence [8], in particular in daily clinical practice.
Health insurance data on filled prescriptions
(pharmacy refill)
The health insurance company provided records on
filled prescriptions for AIs for each patient. Patients
were supposed to collect one pill package per month
(contains 30 pills per package) at the pharmacy. E.g. the
should-be-value for 6 months is 6. The medication-
possession ratio (MPR) determined the number of pre-
scriptions the study patients actually collected at the
pharmacy (and that were then submitted to the health
insurer) in relation to the should-be value for six months
Table 1 Clinical and sociodemographic data (N = 242)
Frequency (%)
Age Median (SD) 65.00 y (8.3y)
Range 40-84y
Marital status Single 18 (8.4%)
Partnership, marriage 135 (63.1%)
Divorced, separated 28 (13.1%)
Widowed 33 (15.4%)






Histological classification Invasive 226 (93.4%)
In situ 15 (6.2%)
Missing 1 (0.4%)
Grading Grade I 35 (14.5%)
Grade II 176 (72.7%)




Median (SD) 26.7 (19.1) mo.
Range 0.7- 89.5 mo.
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the first prescription to the assessment time-point.
Patients who refilled their prescription more than 90%
of the time were considered adherent and those who
refilled it less than 90% of the time non-adherent. The
selection of this cut-off is in accordance with recom-
mendations in the adherence literature [20]. These Time
gaps spent without medication were self-evident.
Determination of AI plasma concentrations
For the determination of anastrozole plasma concentra-
tions, a liquid chromatography tandem mass spectrom-
etry method was developed and fully validated according
to the guidelines for clinical and forensic toxicology.
Methodological procedures have been described else-
where [21]. Anastrozole plasma concentrations below
the limit of quantification were defined as indicative for
non-adherence.
Statistical analysis
Sample characteristics are given as frequencies, means,
standard deviations and ranges. Adherence rates are pre-
sented as percentage with confidence intervals for each as-
sessment method in detail. Confidence intervals are
calculated using the adjusted Wald method. Differences
between adherence rates derived from the different meth-
odological measurement approaches were investigated
using McNemar test.
To investigate the employed methods for adherence
measurement with regard to consistency we used the
Spearman rank correlation. For these analyses, we also
adjusted for age and treatment duration using partial
correlation.
We additionally determined the impact of the differing
temporal reference-frames of the methods applied on
methodological comparability. For this purpose, we varied
the time-frames for the observation period of medication
intake derived from the insurance as follows: previous
month, previous 3 months, previous 4 months and previ-
ous 6 months to the assessment time-point. Additionally,
we extracted the single questions of the SMAQ referring
to the time-frames of intake of last weekend, the previous
week and the previous 3 months; we separately analyzed
the association of these single items as well as the different
time-frames of the insurance data with the other methods




From June 2009 to May 2010, 276 breast cancer patients
receiving anastrazole were identified as eligible for inclu-
sion in this analysis. A total of 242 patients provided writ-
ten informed consent, 34 (12.3%) declined to participate.Main reasons for non-participation were organizational
and logistic problems. There were no significant differ-
ences between patients who participated and those who
declined with regard to clinical and sociodemographic
variables.
Patients varied in age between 40 and 84 years, with a
median age of 65.0 (SD 8.3) years. Median treatment
duration was 26.7 months (SD 19.1, range 0.7-89.5) on
average. About 8% of patients had been undergoing ana-
strazole treatment for >5 years due to their participation
in a trial investigating the efficacy of extended treatment
duration. The most frequent histopathologic cancer type
in this study sample was invasive carcinoma (93.6%), the
most frequent grade was grade II carcinoma (72.7%). For
further details, see Table 1.
The determined AI plasma concentrations ranged be-
tween 5.4 and 90.7 ng/ml. The plasma samples of four
patients showed concentrations below the quantification
limit. Please find details on the distribution of anastrazole
Figure 1 Distribution of anastrazole serum concentrations (presented in ng/ml).
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been presented elsewhere [21].
Comparison of methods for adherence measurement
The comparison of self-reported adherence, physician-
rated adherence, prescription refill and AI plasma con-
centration revealed moderate concordance between
methods. Overall, significant (p < 0.05) correlations ran-
ging from r = 0.189 to r = 0.369 were found across all
methods. Highest correlations were seen between phys-
ician ratings and self-reports, namely r = 0.369 (p <
0.001), lowest between prescription refill and self-report
(r = 0.189, p = 0.050). Details are listed on Table 2.
The adjustment for treatment duration and age by means
of partial correlation had no relevant effect on results
regarding the comparison of methods (results not shown).
Impact of different time-frames/ temporal
reference-frames on concordance between methods
Analyses of the impact of the differing time-frames of the
methods applied for adherence measurement revealedTable 2 Correlation of methods for adherence measurement
Self-report (n = 186) Physician rating (n=211
r p r p
Self-report 1 - 0.369 <0.001*
Physician rating 1 -
Prescription refill
Plasma concentration
*indicates significant correlation (p<0.05).the following results: The shorter the time-intervals for
refilled prescriptions were defined, the smaller was the
correlation with the other methodological approaches
(see Table 3). The SMAQ-question referring to a medica-
tion intake over the previous 3 months was not signifi-
cantly associated with the 3-month time-interval of
prescription refill (r = 0.120, p = 0.183) but significantly
with the 6-month interval (r = 0.197, p = 0.038). Add-
itionally, the 6-month time-frame for medication intake
was not associated with the SMAQ question for medica-
tion intake at the previous weekend (r = −0.13, p = 0.889).
These results suggest a 6-month time-frame for the
method of prescription refill, to better capture adher-
ence behavior compared to shorter time-frames.
Evaluation of adherence to AI
Overall, high adherence rates of 77.8%-98.2% were
observed across all assessment methods (see Table 4).
Physician ratings revealed highest adherence rates
(98.2%), and overall prescription refill the lowest adher-
ence rates (78%). We further determined differences of) Prescription refill (n=121) Plasma concentration (n=223)
r p r p
0.189 0.050* 0.223 0.002*
0.243 0.006* 0.265 <0.001*
1 - 0.251 0.005*
1 -
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test and observed significantly higher adherence rates
indicated by plasma concentration compared to the
other methodological approaches. Also adherence rates
derived from physicians’ ratings were significantly higher
than self-reported adherence and adherence indicated by
prescription refill. Further details are summarized
Table 4.
Discussion
In recent years, the use of oral anticancer treatment,
particularly preventive treatments such as AI therapy,
has been expanding and it is likely to further increase in
the future [22]. Patient adherence is essential for the
success of disease management [23], but should not be
taken for granted, as growing evidence on non-
adherence indicates. Drawing conclusions on actual
adherence rates in breast cancer patients is limited by
considerable discordance in results due to methodo-
logical inconsistency across studies and by the various
measurement methods employed.
Herein, we report on a comparison of four methodo-
logical approaches for adherence assessment in patients
receiving AI treatment in order to investigate
consistency of results determined by self-report, phys-
ician rating, refill records and the measurement of sub-
stance plasma concentrations. To the best of our
knowledge, this is the first study directly comparing
these four measurement approaches in this patient
population.
The methods implemented in our study revealed ad-
herence rates between 78% and 98%, reflecting well-
known inconsistencies for estimations of adherence to
endocrine agents. These numbers are in the higher
bracket of the 20%-100% range reported in the literature
[6,7]. Chlebowski and colleagues (2006) quote adherence
rates of 72%-77% across adjuvant clinical breast cancer
trials and of 54%-80% in breast cancer prevention trials,
regardless of method or type of endocrine agent. How-
ever, very recent studies implementing single methods of
adherence assessment report highly contradictory results
[24,25]. This might be attributed to the heterogeneity of
study designs. Therefore, because of the remarkable het-
erogeneity of reported adherence rates and of methods
of determination used, a comparison of the different
methods appears to be of particular relevamce.
Our study results suggest an at most modest concord-
ance between adherence measures tested in a sample of
breast cancer patients receiving endocrine treatment.
Given correlations of 0.2-0.4, the comparability of results
using these study methods is rather limited.
This observation is consistent with the literature on
adherence in chronic disease. In a study by Dunbar-
Jacobs and colleagues [26] the comparison of self-report(7-day recall), MEMS (Medication Event Monitoring
System) and pill count to assess adherence to lipid-
lowering medications revealed a lack of correlation be-
tween measures despite sample homogeneity (regarding
observation period and treatment). Additionally, the as-
sociation between self-report and MEMS in a sample of
rheumatoid arthritis patients approached zero [9].
Evidence on the subject of comparability of methodo-
logical approaches for measurement of adherence to AIs
is scarce. Ziller and colleagues [16,27] reported a signifi-
cant gap between self-reports and prescription refills for
adherence to tamoxifen and anastrozole. They found
non-adherence rates of 20%-31% on the basis of pre-
scription refill records and perfect self-reported adher-
ence (100%). In an earlier study by Waterhouse and
colleagues [3] in 24 patients receiving tamoxifen, 98%
were classified as adherent using self-reports and 92%
using pill counts, but only 69% by means of MEMS. The
self-report questionnaire and pill count taken together
identified about 17% of patients with poor adherence,
whereas MEMS found that 75% of the cohort was less
than 80% adherent to the tamoxifen regimen.
Our findings suggest a strong dependence of the esti-
mated adherence rates on the specific measurement
method used. As assumed in previous studies [3,16]
methodological shortcomings assigned to each measure-
ment approach may serve as an explanation for these
discrepancies. The following limitations need to be con-
sidered when interpreting our findings:
Two major attributes of the determination of sub-
stance plasma concentrations are its high level of accur-
acy and objectiveness [28,29]. Since concentrations of
one single anastrozole dose can be detected several days
after cessation (mean anastrozole elimination half-life
45.4 – 50 h [30]) the mere verification of the substance
is not indicative of regular medication intake. On the
other hand, inter-patient variations in AI elimination
can cause highly variable plasma concentrations despite
regular drug intake. Farmer et al. [31] suggested that this
method simply shows whether the patient recently took
a dose of the drug, but does not quantify the manner in
which the patient took the drug or any fluctuation in
medication intake. Concurrently, interindividual differ-
ences in drug pharmacokinetics challenge an appropriate
definition of a threshold for plasma concentrations indi-
cating (non-) adherence. Urquhart [2] claims biological
variability in drug response to be the main obstacle to
using biological markers for adherence.
Moreover, a lack of evidence on those plasma level re-
lationship limits the interpretation of individual values.
Beer and colleagues [21] suggested that those patients
with values below or close to the 10th percentile of the
study population are likely not adhering to the regime
prescribed, regardless of time since intake. Nonetheless,
Table 3 Impact of differing time-frames on correlations between methods
Prescription refill Physician rating Plasma concentration Self-report
r p r p r p
Prescription refill – previous month 0.090 0.349 −0.071 0.470 0.112 0.276
Prescription refill – 3months 0.105 0.226 0.050 0.573 0.115 0.218
Prescription refill – 4months 0.194 0.021* 0.175 0.040* 0.167 0.069
Prescription refill – 6months 0.243 0.006* 0.251 0.005* 0.189 0.050#
*indicates significant correlation: p<0.05, # indicates significant correlation: p=0.050.
Oberguggenberger et al. BMC Cancer 2012, 12:474 Page 7 of 9
http://www.biomedcentral.com/1471-2407/12/474they claim concentrations at the lower end of the distri-
bution to be indicative, but not confirmative, of non-
adherence and recommend repeated assessments as a
more qualified strategy for assessing adherence. There-
fore, classifying only those patients with plasma concen-
trations below the quantification limit as non-adherent
we may have underestimated non-adherence behavior in
this patient population. Moreover, this approach does
not consider interindividual differences for metaboliza-
tion. In order to be able to use the determination of AI
plasma concentrations to evaluate adherence, clear
thresholds for adequate plasma concentrations are
needed. On the other hand by using such a conservative
approach, we clearly reduced the site of overestimating
adherence.
Results based on prescription refills strongly depend
on the threshold for the medication-possession ratio
defined as indicating adherence. The determination of
an adequate medication-possession ratio is recom-
mended inconsistently in the available literature, namely
between 80% and 95%. The level of medication intake
required to achieve a therapeutic efficacy of endocrine
agents is still unclear and challenges the definition of
this threshold. In contrast to Ziller and colleagues [16]
and Waterhouse and colleagues [3], we defined a value
of ≥ 90% as satisfactory following Dunbar-Jacob and Ser-
eika [20], who claimed the majority of patients to adhere
above the 90% level. This percentage appeared to beTable 4 Overall adherence rates across methods
Assessment Method Number of patients (%)
Adherent CL 95%
Plasma concentration a 98.2% 95-99%
Physician rating 92.1%* 88-95%
Prescription refill (6months)b 85.3%* 78-90%
Self-rating 82.6%*+ 77-87%
Overall prescription refill b 77.8%*+ 70-83%
a plasma concentrations below the quantification limit indicate non-adherence
(see Methods section).
b an MPR of >90% was classified as adherent.
* significant lower adherence rate than adherence rate indicated by plasma
concentration.
+ significant lower adherence rate than adherence rate indicated by
physician-rating.persistent across measures and over time and was thus
regarded as adequate for this study. However, the key
obstacle presented by this measure is the underlying
premise that refill equals medication intake. This prem-
ise is invalid if patients refill their medication, particu-
larly in the case of low out-of-pocket costs, but are
reluctant regarding intake. Moreover, patients who never
filled any prescription or developed metastatic disease
are lost to this approach.
Lacking a validated self-report questionnaire specific
for breast cancer patients receiving AIs we used the
SMAQ, which considers the impact of iatrogenic harm.
After adaptation for use in our patient sample, a German
version of the questionnaire was deemed appropriate for
patients receiving any type of endocrine treatment. Yet,
we are aware of the shortcoming of lacking validation.
In this context, the inconsistent use of a great variety of
self-report measures further limits data comparability
[31-34].
Proxy-rated adherence by the treating physician can be
susceptible to bias in terms of overestimation. Treating
clinicians seem to be at risk for inaccurately estimating
adherence, either because they are unaware of their
patient‘s poor intake behavior or simply underestimate it
[35-37]. The fact that the second highest adherence rates
in the present study were derived from the proxy ratings
partly support this assumption.
Besides the limitations distinctive to each measure-
ment method, there are some more general methodo-
logical aspects of this study which might contribute to
the observed difference between methods. First, the se-
lection of non-adherence cut-offs is somewhat arbitrary
for all methods which impacts on prevalence rates.
Nonetheless, the subject of defining satisfactory cut-off
levels is a common problem in adherence research and
has been heterogeneously discussed in the literature.
Second, differing time-frames of adherence measure-
ment methods could have impacted on the comparabil-
ity of the approaches. However, we considered this
subject by varying time-frames and could illustrate dif-
fering time-frames to have little effect on methodological
comparability. Finally, acknowledging the shortcomings
of a cross-sectional design for the investigation of an
issue that might be influenced by time (of medication
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ence measurement.
Conclusion
In conclusion, this study helps elucidating some of
the underlying reasons for discrepancies of reported
adherence data for endocrine agents. Our findings show
that the impact of methodology used is of considerable
importance when investigating adherence. In order to
arrive at a more accurate assessment and to subse-
quently obtain more precise estimates of adherence rates
in this patient population, it is mandatory to develop
and validate instruments specific to patients receiving
endocrine agents for breast cancer treatment. In
addition, the determination of AI-serum concentrations
at regular intervals may provide a meaningful measure
for patients’ adherence.
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